Anzeige
Mehr »
Login
Mittwoch, 01.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Uran Boom: Die Bullen starten durch - spektakuläre Kursgewinne möglich
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

'DDT Doctor' Caught Misrepresenting Stanford AGAIN

PALO ALTO, Calif., Oct. 16, 2012 /PRNewswire-USNewswire/ -- The following is being released by the California Right to Know Campaign:

Stanford University is investigating the continued misuse of the university's name to push a political agenda to oppose Proposition 37. Today, new evidence was presented to Stanford documenting how the No on 37 campaign has repeatedly misrepresented the affiliation of their lead spokesperson, Dr. Henry Miller, in campaign ads, in violation of Stanford University policy.

The No on 37 campaign first landed in trouble with Stanford two weeks ago, when their first television ad falsely identified Miller, a researcher at the Hoover Institution, as "M.D., Stanford." Stanford ordered the ad to be reshot to correct the misidentification and remove Stanford's buildings from the background, as the Los Angeles Times reported.

Six days later, voters across the state received a No on 37 propaganda mailer that falsely identified Miller as an MD at Stanford. In a letter to Stanford, Yes on 37 attorney Joe Sandler notified Stanford Vice President and General Council Debra Zumwalt about the violation - pointing out that the mailing arrived a week after Stanford insisted on the correction.

According to the Stanford press department, the No on 37 Campaign said the mailer went to a "small list" and it wouldn't happen again. But today, the Yes on 37 campaign notified Stanford that Miller is falsely identified in another mailer, this one a large brochure. An online ad featuring Miller also appears to have Stanford's buildings in the background.

(see images here)

Sandler asked Zumwalt to put a stop to communications that violate university policy and to clarify to the public that they have not taken a position on Proposition 37.

"Opponents of our right to know are waging a campaign of deception in California, funded by the world's largest pesticide companies and fronted by a doctor who has done the dirty work of the pesticide companies for years, as evidenced by Miller's campaign to re-introduce DDT," said Yes on 37 spokesperson Stacy Malkan.

"The No on 37 campaign has put Henry Miller in front of millions of California voters as a credible source, yet the public has no idea that Dr. Miller's extreme views are far outside the mainstream of acceptable science. We want to know: Does the No on 37 campaign stand behind Miller's fringe views on tobacco, climate change, nuclear radiation and DDT?"

Yesterday, the Right to Know campaign sent a letter to No on 37 campaign manager Kathy Fairbanks asking if she stands behind Miller's radical scientific views.

Read about the dubious credibility of No on 37 Science Spokesperson Henry Miller here.

Paid for by Yes on 37 For Your Right to Know if Your Food Has Been Genetically Engineered Supported by Consumer Advocates Makers of Organic Products and California Farmers, Major funding by Mercola Health Resources LLC and Organic Consumers Fund. 5940 College Ave, Suite F, Oakland, CA 94618, United States

http://www.carighttoknow.org/_ddt_doctor

SOURCE California Right to Know Campaign

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.